Evaluation of two highly-multiplexed custom panels for Massively parallel semiconductor sequencing on paraffin DNA

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Kotoula, Vassiliki ^a   Lyberopoulou, Aggeliki ^a   Papadopoulou, Kyriaki ^a   Charalambous, Elpida ^a   Alexopoulou, Zoi ^b   Gakou, Chryssa ^a   Lakis, Sotiris ^a   Tsolaki, Eleftheria ^a   Lilakos, Konstantinos ^c   Fountzilas, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Health Data Specialists Ltd   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FORMALDEHYDE; PARAFFIN; TUMOR PROTEIN;

AMPLICON; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER TISSUE; DNA DETERMINATION; GENETIC PROCEDURES; GENOTYPE; HUMAN; MASSIVELY PARALLEL SEMICONDUCTOR SEQUENCING; RELIABILITY; BREAST NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DEVICES; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SEMICONDUCTOR; TISSUE FIXATION;

BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FORMALDEHYDE; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; PILOT PROJECTS; SEMICONDUCTORS; TISSUE FIXATION;

EID: 84934945778     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128818     Document Type: Article

References (47)

1. Fu Q, Wang F, Wang H, Xu F, Zaneveld JE, Ren H, et al. Next-generation sequencing-based molecular diagnosis of a Chinese patient cohort with autosomal recessive retinitis pigmentosa. Investigative ophthalmology & visual science. 2013;54(2013):4158-66. doi:10.1167/iovs.13-11672 PMID:23661369; PubMed Central PMCID: PMC3684217.
2. Millat G, Chanavat V, Rousson R. Evaluation of a new high-throughput next-generation sequencing method based on a custom AmpliSeq library and ion torrent PGM sequencing for the rapid detection of genetic variations in long QT syndrome. Molecular diagnosis & therapy. 2014;18(2014):533-9. doi:10. 1007/s40291-014-0099-y PMID:24687331.
3. Schaefer E, Helms P, Marcellin L, Desprez P, Billaud P, Chanavat V, et al. Next-generation sequencing (NGS) as a fast molecular diagnosis tool for left ventricular noncompaction in an infant with compound mutations in the MYBPC3 gene. European journal of medical genetics. 2014;57(2014):129-32. doi:10. 1016/j.ejmg.2014.02.015 PMID:24602869.
4. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2014. doi:10.1002/cncr.29010 PMID:25186627.
5. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, Marko AC, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. The Journal of molecular diagnostics: JMD. 2013;15(2013):234-47. doi:10.1016/j. jmoldx.2012.11.006 PMID:23321017.
6. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, et al. Clinical validation of a nextgeneration sequencing screen for mutational hotspots in 46 cancer-related genes. The Journal of molecular diagnostics: JMD. 2013;15(5):607-22. doi:10.1016/j.jmoldx.2013.05.003 PMID:23810757.
7. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer discovery. 2012;2(2012):82-93. doi:10.1158/2159-8290. CD-11-0184 PMID:22585170; PubMed Central PMCID: PMC3353152.
8. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. The Journal of clinical endocrinology and metabolism. 2013;98(2013):E1852-60. doi:10.1210/jc.2013-2292 PMID:23979959; PubMed Central PMCID: PMC3816258.
9. Salto-Tellez M, Gonzalez de Castro D. Next-generation sequencing: a change of paradigm in molecular diagnostic validation. The Journal of pathology. 2014;234(2014):5-10. doi:10.1002/path.4365 PMID:24756835.
10. McCall CM, Mosier S, Thiess M, Debeljak M, Pallavajjala A, Beierl K, et al. False positives in multiplex PCR-based next-generation sequencing have unique signatures. The Journal of molecular diagnostics: JMD. 2014;16(2014):541-9. doi:10.1016/j.jmoldx.2014.06.001 PMID:25017478; PubMed Central PMCID: PMC4188281.
11. Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, et al. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. British journal of cancer. 2014;111(10):2014-23. doi:10.1038/bjc.2014.518 PMID:25314059; PubMed Central PMCID: PMC4229640.
12. Zhang L, Chen L, Sah S, Latham GJ, Patel R, Song Q, et al. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. The oncologist. 2014;19(2014):336-43. doi:10.1634/theoncologist.2013-0180 PMID:24664487; PubMed Central PMCID: PMC3983811.
13. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011;475(2011):348-52. doi:10.1038/nature10242 PMID:21776081.
14. Li X, Buckton AJ, Wilkinson SL, John S, Walsh R, Novotny T, et al. Towards clinical molecular diagnosis of inherited cardiac conditions: a comparison of bench-top genome DNA sequencers. PloS one. 2013;8(2013):e67744. doi:10.1371/journal.pone.0067744 PMID:23861798; PubMed Central PMCID: PMC3701544.
15. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC genomics. 2012;13:341. doi:10.1186/1471-2164-13-341 PMID:22827831; PubMed Central PMCID: PMC3431227.
16. Wang Y, Wen Z, Shen J, Cheng W, Li J, Qin X, et al. Comparison of the performance of Ion Torrent chips in noninvasive prenatal trisomy detection. J Hum Genet. 2014;59(2014):393-6. Epub 2014/06/13. jhg201440 [pii] doi:10.1038/jhg.2014.40 PMID:24919645.
17. Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, Leamon J, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. The Journal of molecular diagnostics: JMD. 2013;15(2013):171-6. doi:10.1016/j.jmoldx.2012.09.003 PMID:23274167.
18. Simen BB, Yin L, Goswami CP, Davis KO, Bajaj R, Gong JZ, et al. Validation of a Next-Generation-Sequencing Cancer Panel for Use in the Clinical Laboratory. Archives of pathology & laboratory medicine. 2014. doi:10.5858/arpa.2013-0710-OA PMID:25356985.
19. Fang W, Radovich M, Zheng Y, Fu CY, Zhao P, Mao C, et al. 'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients. Oncology letters. 2014;7(2014):1761-6. doi:10.3892/ol. 2014.2047 PMID:24932229; PubMed Central PMCID: PMC4049685.
20. Mafficini A, Amato E, Fassan M, Simbolo M, Antonello D, Vicentini C, et al. Reporting tumor molecular heterogeneity in histopathological diagnosis. PloS one. 2014;9(2014):e104979. doi:10.1371/journal.pone. 0104979 PMID:25127237; PubMed Central PMCID: PMC4134249.
21. Yan B, Kuick CH, Lim M, Venkataraman K, Tennakoon C, Loh E, et al. Platform Comparison for Evaluation of ALK Protein Immunohistochemical Expression, Genomic Copy Number and Hotspot Mutation Status in Neuroblastomas. PloS one. 2014;9(2014):e106575. doi:10.1371/journal.pone.0106575 PMID:25188507; PubMed Central PMCID: PMC4154751.
22. Kraus C, Rau TT, Lux P, Erlenbach-Wunsch K, Lohr S, Krumbiegel M, et al. Comprehensive screening for mutations associated with colorectal cancer in unselected cases reveals penetrant and nonpenetrant mutations. International journal of cancer Journal international du cancer. 2014. doi:10.1002/ijc. 29149 PMID:25142776.
23. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2014. doi:10.1002/cncr.29089 PMID:25345567.
24. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, et al. Postoperative dosedense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2008;19(2008):853-60. PMID:18042835.
25. Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, et al. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC cancer. 2014;14:515. doi:10.1186/1471-2407-14-515 PMID:25026897.
26. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al. Postoperative dosedense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2005;16(2005):1762-71. PMID:16148021.
27. Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer:5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast cancer research and treatment. 2012;132(2012):609-19. doi:10.1007/s10549-011-1913-4 PMID:22187126.
28. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature. 2012;486(2012):346-52. Epub 2012/04/24. nature10983 [pii] doi:10.1038/nature10983 PMID:22522925.
29. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(2012):395-9. doi:10.1038/nature10933 PMID:22495314; PubMed Central PMCID: PMC3863681.
30. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(2012):400-4. Epub 2012/06/23. nature11017 [pii] doi:10.1038/nature11017 PMID:22722201.
31. TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(2012):61-70. Epub 2012/09/25. nature11412 [pii] doi:10.1038/nature11412 PMID:23000897.
32. Stavropoulou AV, Fostira F, Pertesi M, Tsitlaidou M, Voutsinas GE, Triantafyllidou O, et al. Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PloS one. 2013;8(2013):e58182. doi:10.1371/journal.pone.0058182 PMID:23536787; PubMed Central PMCID: PMC3594241.
33. Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PloS one. 2009;4(2009):e7746. doi:10.1371/journal.pone.0007746 PMID:19888477; PubMed Central PMCID: PMC2768905.
34. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(2009):1754-60. doi:10.1093/bioinformatics/btp324 PMID:19451168; PubMed Central PMCID: PMC2705234.
35. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(2010):589-95. doi:10.1093/bioinformatics/btp698 PMID:20080505; PubMed Central PMCID: PMC2828108.
36. Ning Z, Cox AJ, Mullikin JC. SSAHA: a fast search method for large DNA databases. Genome research. 2001;11(2001):1725-9. doi:10.1101/gr.194201 PMID:11591649; PubMed Central PMCID: PMC311141.
37. Li H. Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly. Bioinformatics. 2012;28(2012):1838-44. doi:10.1093/bioinformatics/bts280 PMID:22569178; PubMed Central PMCID: PMC3389770.
38. Spencer DH, Sehn JK, Abel HJ, Watson MA, Pfeifer JD, Duncavage EJ. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. The Journal of molecular diagnostics: JMD. 2013;15(2013):623-33. doi:10.1016/j.jmoldx.2013.05.004 PMID:23810758.
39. Song S, Nones K, Miller D, Harliwong I, Kassahn KS, Pinese M, et al. qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PloS one. 2012;7(2012):e45835. PMID:23049875. doi:10.1371/journal.pone.0045835
40. Kol N, Shomron N. Assembly algorithms for deep sequencing data: basics and pitfalls. Methods in molecular biology. 2013;1038:81-91. doi:10.1007/978-1-62703-514-9-5 PMID:23872970.
41. Raphael BJ, Dobson JR, Oesper L, Vandin F. Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome medicine. 2014;6(2014):5. doi:10.1186/gm524 PMID:24479672; PubMed Central PMCID: PMC3978567.
42. Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. Journal of clinical pathology. 2014. doi:10.1136/jclinpath-2014-202405 PMID:25004944.
43. Wall JD, Tang LF, Zerbe B, Kvale MN, Kwok PY, Schaefer C, et al. Estimating genotype error rates from high-coverage next-generation sequence data. Genome research. 2014. doi:10.1101/gr.168393. 113 PMID:25304867.
44. Wong SQ, Li J, Tan AY, Vedururu R, Pang JM, Do H, et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC medical genomics. 2014;7:23. doi:10.1186/1755-8794-7-23 PMID:24885028; PubMed Central PMCID: PMC4032349.
45. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer research. 2012;72(2012):4875-82. doi:10.1158/0008-5472. CAN-12-2217 PMID:23002210; PubMed Central PMCID: PMC3712191.
46. Chen G, Mosier S, Gocke CD, Lin MT, Eshleman JR. Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Molecular diagnosis & therapy. 2014;18(2014):587-93. doi:10. 1007/s40291-014-0115-2 PMID:25091469; PubMed Central PMCID: PMC4175022.
47. Do H, Wong SQ, Li J, Dobrovic A. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clinical chemistry. 2013;59(2013):1376-83. doi:10.1373/clinchem.2012.202390 PMID:23649127.